Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1703 MACS trial in newly diagnosed maximally resected glioblastoma
jRCT1031190035Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carmustine and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Jun 2019; status: active, not recruiting.
02
Drugs
carmustinetemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT1031190035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031190035.